Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential disease-modifying treatment for IgAN will be presented at 60th European Renal ...
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for ...
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction ...
Treatment with atacicept led to a statistically significant 42% reduction in UPCR compared with placebo at week 36. Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation ...
The designation was based on data from the phase 2b ORIGIN trial, which demonstrated a clinically meaningful reduction in proteinuria with atacicept. The Food and Drug Administration (FDA) has granted ...
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations ...
BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results